10. CLINICAL, LABORATORY CHARACTERISTICS OF WHITMORE CHILDREN PATIENTS TREATED AT THE NATIONAL CHILD’EN'S HOSPITAL

Le Thi Yen1, Nguyen Van Lam1, Tran Thanh Duong2, Hoang Thi Bich Ngoc1, Phan Thi Thu Chung1, Tran Minh Dien1
1 Vietnam National Children’s Hospital
2 National Institute of Nutrition

Main Article Content

Abstract

Whitmore is an infectious disease caused by the bacteria Burkholderia pseudomallei in humans and animals. It is not common in children but has diverse clinical features, difficult to diagnose, and a high mortality rate.


Objective: To describe the clinical and subclinical characteristics of Whitmore in patients treated at the National Children’s Hospital.


Research methods: Retrospective and prospective descriptive study on 45 children diagnosed with Whitmore and treated at the National Children’s Hospital from January 1, 2017 to December 31, 2023.


Results: Of the total 45 pediatric patients diagnosed with Whitmore. The number of patients ≤ 5 years old is 26 (57.8%), the male/female ratio is 2/1; 91.1% of patients have no underlying diseases. The most common clinical manifestation was angle-of-jaw abscess in 26/45 cases, accounting for 57.8%, and bacteremia in 12/45 cases, accounting for 26.7%. Septic shock accounted for 22.2% of children infected with Whitmore. The sensitivity rate of B. pseudomallei to Meropenem and Imipenem antibiotics was 100%. The resistance rate to Ceftazidime antibiotics was 2.5%; Amoxicillin/Clavulanic Acid was 5% and Trimethoprim/Sulfamethoxazole was 23.5%.


Conclusions: Whitmore is common disease in the age group ≤ 5, with the most common clinical presentation being parotid abscess accounting for 57.8%. The rate of bacteria sensitive to Carbapenem was 100% and the resistance rate to Ceftazidime was 2.4%.

Article Details

References

Wiersinga W.J, Virk H.S, Torres A.G et al, Melioidosis, Nat Rev Dis Primers, 2018, 4 (1): 1-22.
[2] Jarrett O, Seng S, Fitzgerald D.A, Paediatric melioidosis, Paediatr Respir Rev, Published online November, 24, 2023: S1526-0542(23)00079-9.
[3] Meumann E.M, Limmathurotsakul D, Dunachie S.J, Wiersinga W.J, Currie B.J, Burkholderia pseudomallei and melioidosis, Nat Rev Microbiol, 2024, 22 (3): 155-169.
[4] Bộ Y tế, Quyết định số 6101/QĐ-BYT ngày 30/12/2019 về việc ban hành Hướng dẫn chẩn đoán, điều trị bệnh Whitmore.
[5] Arjun C, Moritz B, Thyl M, Keang S, Improving Treatment and Outcomes for Melioidosis in Children, Northern Cambodia, 2009-2018, Emerging infectious diseases, 2021, 27 (4).
[6] Currie B.J, Ward L, Cheng A.C, The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study, PLoS Negl Trop Dis, 2010, 4 (11): e900.
[7] Easton A, Haque A, Chu K et al, A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei, J Infect Dis., 2007, 195 (1): 99-107.
[8] Cheng A.C, Obrien M, Jacups S.P et al, C-reactive protein in the diagnosis of melioidosis, Am J Trop Med Hyg., 2004, 70 (5): 580-582.
[9] Pham T.S, König E, Bui T.T et al, Newly detected paediatric melioidosis cases in a single referral children’s hospital in Ho Chi Minh city indicate the probable underrecognition of melioidosis in South Vietnam, Trans R Soc Trop Med Hyg., 2024, 118 (3): 190-198.
[10] Vanaporn W, Premjit A, Natnaree S et al, Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand, Antimicrobial agents and chemotherapy, 2011, 55 (11).